Literature DB >> 24218111

After the cure: management of HCV after achievement of SVR.

Zachary A Zator1, Raymond T Chung.   

Abstract

Co-infection with HIV and HCV is associated with accelerated progression of liver disease and increased complications compared with HCV infection alone. Treatment of HCV and achievement of a sustained virologic response (SVR) can improve outcomes in these patients. Even after clearance of the hepatitis C virus, however, patients remain at risk, albeit diminished, for the complications of chronic liver disease. As such, longitudinal monitoring of treated patients remains important for clinicians caring for this population. This article summarizes the benefits and persistent risks after attaining SVR. It reviews the natural history of fibrosis and addresses the monitoring and management of progressive liver disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24218111     DOI: 10.1007/s11904-013-0181-9

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  52 in total

1.  Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.

Authors:  Shruti H Mehta; Gregory M Lucas; Lisa B Mirel; Michael Torbenson; Yvonne Higgins; Richard D Moore; David L Thomas; Mark S Sulkowski
Journal:  AIDS       Date:  2006-11-28       Impact factor: 4.177

2.  Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.

Authors:  Guadalupe Garcia-Tsao; Arun J Sanyal; Norman D Grace; William Carey
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

3.  The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial.

Authors:  Jean-Marc Chapplain; Eric Bellissant; Dominique Guyader; Jean-Michel Molina; Isabelle Poizot-Martin; Philippe Perré; Gilles Pialoux; Bruno Turlin; Catherine Mouchel; Alain Renault; Christian Michelet
Journal:  J Infect       Date:  2013-06-22       Impact factor: 6.072

4.  Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care.

Authors:  Hamish A Innes; Sharon J Hutchinson; Samuel Allen; Diptendu Bhattacharyya; Peter Bramley; Toby E S Delahooke; John F Dillon; Ewan Forrest; Andrew Fraser; Ruth Gillespie; David J Goldberg; Nicholas Kennedy; Scott McDonald; Allan McLeod; Peter R Mills; Judith Morris; Peter Hayes
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

5.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

6.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Authors:  Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren
Journal:  Arch Intern Med       Date:  2006 Aug 14-28

7.  Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome.

Authors:  Massimo Puoti; Raffaele Bruno; Vincent Soriano; Francesco Donato; Giovanni Battista Gaeta; Gian Paolo Quinzan; Davide Precone; Umberto Gelatti; Victor Asensi; Emanuela Vaccher
Journal:  AIDS       Date:  2004-11-19       Impact factor: 4.177

8.  Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients.

Authors:  José Medrano; Pablo Barreiro; Salvador Resino; Paula Tuma; Violeta Rodríguez; Eugenia Vispo; Pablo Labarga; Antonio Madejón; Javier García-Samaniego; Inmaculada Jiménez-Nácher; Luz Martín-Carbonero; Vincent Soriano
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079

9.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  9 in total

1.  Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders.

Authors:  Myrna L Cozen; James C Ryan; Hui Shen; Ramsey Cheung; David E Kaplan; Christine Pocha; Norbert Brau; Ayse Aytaman; Warren N Schmidt; Marcos Pedrosa; Bhupinderjit S Anand; Kyong-Mi Chang; Timothy Morgan; Alexander Monto
Journal:  Dig Dis Sci       Date:  2016-04-08       Impact factor: 3.199

Review 2.  Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C.

Authors:  Karoll J Cortez; Shyam Kottilil
Journal:  Ther Adv Chronic Dis       Date:  2015-01       Impact factor: 5.091

3.  Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response.

Authors:  José Luis Casado; María Angeles Esteban; Sara Bañón; Ana Moreno; María J Perez-Elías; María Luisa Mateos; Santiago Moreno; Carmen Quereda
Journal:  Dig Dis Sci       Date:  2015-06-26       Impact factor: 3.199

4.  Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study.

Authors:  Joshua A Barocas; Alexandra Savinkina; Sara Lodi; Rachel L Epstein; Tara C Bouton; Heather Sperring; Heather E Hsu; Karen R Jacobson; Elissa M Schechter-Perkins; Benjamin P Linas; Laura F White
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

5.  Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection.

Authors:  Lindsay Matthews; David E Kleiner; Cheryl Chairez; Maryellen McManus; Mary Jane Nettles; Kira Zemanick; Caryn Gee Morse; Debra Benator; Joseph A Kovacs; Colleen Hadigan
Journal:  AIDS Res Hum Retroviruses       Date:  2015-08-24       Impact factor: 2.205

Review 6.  HIV, Aging, and Viral Coinfections: Taking the Long View.

Authors:  Tamar H Taddei; Vincent Lo Re; Amy C Justice
Journal:  Curr HIV/AIDS Rep       Date:  2016-10       Impact factor: 5.071

7.  Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance.

Authors:  Ryan A Hlady; Xia Zhao; Louis Y El Khoury; Aesis Luna; Kien Pham; Qunfeng Wu; Jeong-Heon Lee; Nikolaos T Pyrsopoulos; Chen Liu; Keith D Robertson
Journal:  Hepatology       Date:  2021-12-15       Impact factor: 17.298

8.  Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.

Authors:  Joshua A Barocas; Jake R Morgan; David A Fiellin; Bruce R Schackman; Golnaz Eftekhari Yazdi; Michael D Stein; Kenneth A Freedberg; Benjamin P Linas
Journal:  Int J Drug Policy       Date:  2019-05-10

9.  Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States.

Authors:  Joshua A Barocas; Abriana Tasillo; Golnaz Eftekhari Yazdi; Jianing Wang; Claudia Vellozzi; Susan Hariri; Cheryl Isenhour; Liisa Randall; John W Ward; Jonathan Mermin; Joshua A Salomon; Benjamin P Linas
Journal:  Clin Infect Dis       Date:  2018-08-01       Impact factor: 20.999

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.